Opthea to Showcase AMD Therapy Breakthroughs
Company Announcements

Opthea to Showcase AMD Therapy Breakthroughs

Opthea Limited (AU:OPT) has released an update.

Opthea Limited, a biopharmaceutical firm, will present their advancements in treating wet AMD with their leading candidate, sozinibercept, at the Innovate Retina Meeting. Dr. David Boyer will discuss the Phase 2b trial results and the ongoing Phase 3 trials aimed at improving treatment efficacy over standard therapies. The company is focused on addressing the significant unmet needs in retinal diseases like wet AMD and diabetic macular edema.

For further insights into AU:OPT stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskOpthea to Highlight Promising AMD Therapy at Key Events
TipRanks Australian Auto-Generated NewsdeskOpthea Limited to Present at Key November Investor Conferences
TipRanks Australian Auto-Generated NewsdeskOpthea Set to Highlight Innovations at Investor Conferences
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App